Neuphoria Therapeutics (NEUP) director Alan Fisher awarded 17,073 RSUs

Rhea-AI Filing Summary

Neuphoria Therapeutics Inc. director Alan Fisher reported a new equity award in the form of restricted stock units (RSUs). On 01/20/2026, he received 17,073 RSUs, each representing the right to receive one share of common stock at no purchase price. After this grant, he beneficially owns 30,731 derivative securities related to the company.

The RSUs were granted under the board of directors’ annual remuneration policy. They will fully vest if Fisher continues to serve the company through the earlier of the day before the next annual shareholder meeting, which is expected to be no later than December 15, 2026, or the effective date of a change in control of the company.

Insights

Equity compensation analyst

Routine RSU grant to director under board pay program.

Neuphoria Therapeutics Inc. granted director Alan Fisher 17,073 restricted stock units on January 20, 2026 at a price of $0 per unit. Each RSU represents the right to receive one share of common stock, and this award increases his total derivative holdings to 30,731 units.

The filing states the grant follows the board’s annual remuneration policy, indicating this is part of standard director compensation rather than a special award. The RSUs vest only if Fisher maintains continuous service through the earlier of the day before the next annual shareholder meeting, expected by December 15, 2026, or a change in control of the company.

This structure aligns director incentives with shareholder outcomes over the coming service period, but the filing does not quantify the award’s size relative to the company or to Fisher’s overall ownership. The information is primarily administrative, documenting ongoing equity-based compensation rather than signaling a change in corporate strategy or financial outlook.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fisher Alan

(Last) (First) (Middle)

100 SUMMIT DRIVE

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Neuphoria Therapeutics Inc. [ NEUP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)(2)	01/20/2026		A		17,073		(3)	(3)	Common Stock	17,073	$0	30,731	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock.

2. The grant of RSUs is pursuant to the Company's Board of Directors annual remuneration policy.

3. Subject to the Reporting Person's continuous service to the Company through the first of the following dates: (a) the day prior to the Company' next annual shareholder meeting (which is expected to be no later than December 15, 2026) or (b) the effective date of a Change in Control of the Company, the RSUs shall fully vest.

	/s/ Elaine Wangsawidjaja, Attorney-in-Fact for Alan Fisher	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Neuphoria Therapeutics (NEUP) report for Alan Fisher?

The company reported that director Alan Fisher received a grant of 17,073 restricted stock units (RSUs) on January 20, 2026 as part of his equity compensation.

How many Neuphoria Therapeutics (NEUP) shares does each RSU for Alan Fisher represent?

Each restricted stock unit reported for Alan Fisher represents a contingent right to receive one share of Neuphoria Therapeutics common stock.

What is Alan Fisher’s total Neuphoria Therapeutics RSU holding after this Form 4?

Following the reported transaction, Alan Fisher beneficially owns 30,731 derivative securities in the form of restricted stock units related to Neuphoria Therapeutics.

What are the vesting conditions for Alan Fisher’s new Neuphoria Therapeutics RSUs?

The 17,073 RSUs will fully vest if Alan Fisher maintains continuous service through the earlier of the day prior to the next annual shareholder meeting (expected no later than December 15, 2026) or the effective date of a change in control of the company.

Is the RSU grant to Alan Fisher a special award or part of a policy at Neuphoria Therapeutics (NEUP)?

The filing states that the RSU grant is made pursuant to the company’s Board of Directors annual remuneration policy, indicating it is part of standard director compensation.

Did Alan Fisher pay anything for the Neuphoria Therapeutics RSUs reported on this Form 4?

No purchase price was reported; the RSUs were granted at $0 per unit as equity compensation.